Goldman Sachs raised the firm’s price target on Legence (LGN) to $63 from $52 and keeps a Buy rating on the shares. The firm came away from the Q4 results with a continued positive view on Legence’s ability to deliver double-digit organic growth through 2027, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGN:
- Legence Corp. Delivers Record Results, Lifts 2026 Outlook
- Tigress Financial sees AI momentum powering gowth for Legence
- Midday Fly By: Carnival cuts forecast on fuel cost, Novartis to buy Excellergy
- Morning Movers: AstraZeneca jumps following tozorakimab trial results
- Legence reports Q4 EPS (55c), consensus 5c